# Corticotropin PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/corticotropin

> Corticotropin, sponsored by ANI PHARMACEUTICALS INC (ANIP): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | corticotropin |
| Codes |  |
| Sponsor | ANI PHARMACEUTICALS INC (ANIP) https://sec-api.dev/companies/anip/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jan 2022: label expansion decision

- Status: completed, approved. Date confidence: month.
- First seen 2025-03-11, last confirmed 2025-03-11.
- Press release filed with the SEC (EX-99) (accession 0001023024-25-000018): "received FDA approval for sNDA with expected Q2 2025 launch Launched January 2022" https://www.sec.gov/Archives/edgar/data/1023024/000102302425000018/a250311anipleerinkconfer.htm

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2024-11-20, last confirmed 2025-03-11.
- Press release filed with the SEC (EX-99) (accession 0001023024-25-000018): "Topline data expected in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1023024/000102302425000018/a250311anipleerinkconfer.htm
- Press release filed with the SEC (EX-99) (accession 0001023024-25-000006): "Topline data expected in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1023024/000102302425000006/exhibit991investordeck20.htm
- Press release filed with the SEC (EX-99) (accession 0001023024-25-000002): "Topline data expected in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1023024/000102302425000002/exhibit992investordeck20.htm
- Press release filed with the SEC (EX-99) (accession 0001023024-24-000106): "Topline data expected in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1023024/000102302424000106/exhibit991investordeck11.htm

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2024-11-20, last confirmed 2025-08-14.
- Press release filed with the SEC (EX-99) (accession 0001023024-25-000058): "Topline data readout expected in Q1 2026 1." https://www.sec.gov/Archives/edgar/data/1023024/000102302425000058/a250604anipjefferiesconf.htm
- Press release filed with the SEC (EX-99) (accession 0001023024-25-000049): "Topline data readout expected in Q1 2026 1." https://www.sec.gov/Archives/edgar/data/1023024/000102302425000049/a250520aniphcwconference.htm
- Press release filed with the SEC (EX-99) (accession 0001023024-25-000018): "Topline data readout expected in Q1 2026 1." https://www.sec.gov/Archives/edgar/data/1023024/000102302425000018/a250311anipleerinkconfer.htm
- Press release filed with the SEC (EX-99) (accession 0001023024-25-000006): "Topline data readout expected in Q1 2026" https://www.sec.gov/Archives/edgar/data/1023024/000102302425000006/exhibit991investordeck20.htm
- Press release filed with the SEC (EX-99) (accession 0001023024-25-000002): "Topline data readout expected in Q1 2026" https://www.sec.gov/Archives/edgar/data/1023024/000102302425000002/exhibit992investordeck20.htm
- Press release filed with the SEC (EX-99) (accession 0001023024-24-000106): "Topline data readout expected in Q1 2026" https://www.sec.gov/Archives/edgar/data/1023024/000102302424000106/exhibit991investordeck11.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-108868): "Topline results from TAMARIND are anticipated in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1683553/000095017025108868/sprb-ex99_1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/corticotropin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Corticotropin PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/corticotropin

```bibtex
@misc{secapidev_pdufa_corticotropin_20261116,
  title        = {Corticotropin PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/corticotropin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_corticotropin_20261116","title":"Corticotropin PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/corticotropin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
